Lates News

AstraZeneca's IL-33 targeting biologic agent tozorakimab has achieved positive results in the third pivotal phase III clinical trial. The results show that tozorakimab significantly and clinically improved the annual rate of moderate to severe acute exacerbations in patients with chronic obstructive pulmonary disease (COPD), both in the primary study population (former smokers) and the overall population (including both former and current smokers, and covering patients with all blood eosinophil levels and all levels of lung function severity grading).